IFM Investors Pty Ltd Sells 102 Shares of Regeneron Pharmaceuticals, Inc. $REGN

IFM Investors Pty Ltd lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,248 shares of the biopharmaceutical company’s stock after selling 102 shares during the period. IFM Investors Pty Ltd’s holdings in Regeneron Pharmaceuticals were worth $13,476,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in REGN. Pinney & Scofield Inc. bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 31 shares in the last quarter. Activest Wealth Management increased its holdings in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 21 shares in the last quarter. Costello Asset Management INC bought a new position in Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Finally, Saudi Central Bank bought a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on REGN shares. UBS Group reissued a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Jefferies Financial Group boosted their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research report on Wednesday, August 27th. Sanford C. Bernstein boosted their price target on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 27th. Rothschild & Co Redburn started coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a “buy” rating and a $890.00 price target on the stock. Finally, Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $817.67.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $555.83 on Thursday. The firm has a 50-day moving average of $563.85 and a 200-day moving average of $581.78. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,170.58. The company has a market cap of $58.91 billion, a PE ratio of 14.01, a price-to-earnings-growth ratio of 1.86 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter last year, the firm posted $11.56 EPS. The company’s quarterly revenue was up 3.6% on a year-over-year basis. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a $0.88 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.